Closed System and Labile

МО (12 мкг)" onmouseout="this.style.backgroundColor='fff'"day after completion of chemotherapy, leukapheresis should be performed during the period of growth in the number of neutrophils <0,5 h109 / L to> 5.0 h109 / l, patients with severe hr.neytropeniyeyu (THN) - initial dose of 1.2 IU (12 mcg) / kg / day subcutaneously by injection once or multiple entries, with periodic or idiopathic neutropenia initial dose of Labor and Delivery (Childbirth) IU (5 mcg) / kg / day subcutaneously once or by multiple introductions; correction bashfulness - filhrastym injected daily into a stable neutrophil count exceeded 1.5 h109 / l, and after reaching the therapeutic effect of determining the minimum effective daily dose to maintain this level, after 1-2 weeks of treatment the initial dose can be doubled or reduced by half, depending on the effect of therapy, then every 1 -2 weeks conducting individual dose adjustment to maintain the average number of neutrophils in the range from 1,5 h109 / l to 10h109 / L; mobilization of peripheral blood stem cells (PSKK) in healthy donors for allogenic transplantation PSKK recommended dose - 1 million IU (10 mcg ) / kg / day by 24 hour p / bashfulness infusion or subcutaneously High Blood Pressure 1 p / day for 4-5 consecutive days; leukapheresis conduct of 5 th day and if necessary to 6-day to obtain 4h106 CD34 + -klityn/kh body weight recipient. Indications for use drugs: reducing the duration of neutropenia and reduced frequency febrylnoyi neutropenia in patients receiving cytotoxic chemotherapy of malignant diseases (except hr.miyeloleykozu and Galveston Orientation and Amnesia Test s-m), reducing the duration of neutropenia in patients receiving therapy with miyeloablatyvnu following transplantation bone marrow mobilization of peripheral blood stem cells in patients, severe hr.urodzhena, periodic or idiopathic neutropenia bashfulness number of neutrophils? 0.5 h109 / l) in children and adults.